Michael Jäger

4 ta ish

Technical University of Munich

1. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

   Peter Ruf, Michael Kluge, Michael Jäger +7

   Maqola20103 iqtibos

   ABIABI:AkademIndex/2026.other.913630

2. Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

   Alexander Burges, Pauline Wimberger, Carolin Kümper +15

   Maqola20073 iqtibos

   ABIABI:AkademIndex/2026.other.913648

3. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

   Peter Ruf, Olivier Gires, Michael Jäger +3

   Maqola20072 iqtibos

   ABIABI:AkademIndex/2026.other.913704

4. Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

   Michael Jäger, A. Schoberth, Peter Ruf +8

   Maqola20112 iqtibos

   ABIABI:AkademIndex/2026.other.913705